Abstract
BackgroundCoronary artery disease is associated with a common mitochondrial DNA alteration, a 4977 bp deletion (mtDNA4977). The role of mtDNA4977 in ischemic stroke is unknown.MethodsReal-time quantitative PCR was performed to quantify total mtDNA and mtDNA4977 in leukocytes in 283 ischemic stroke cases and 135 controls. Ratios of mtDNA4977 to total-mtDNA and total-mtDNA to nuclear-DNA were calculated. Nested PCR and Sanger sequencing were used to confirm undetectable levels of mtDNA4977.ResultsFor 191 patients and 74 control subjects in the male group and 92 patients and 61 control subjects in the female group, there were no significant between-group differences in age, cholesterol level, body mass index, stroke severity, or 4977 deletion. After adjusting for confounding factors, there was no correlation between mtDNA4977 amount and infarction risk, recurrent stroke, or stroke severity. However, mtDNA4977 was undetected in 6.94% subjects, and these individuals had a higher prevalence of stroke than those with detectable mtDNA4977 (OR: 0.181, 95% CI 0.041–0.798, p = 0.024). Additionally, mtDNA4977 status had no effect on stroke prognosis, including stroke severity and recurrent stroke.ConclusionIn conclusion, there was no apparent association between mtDNA4977 deletion and cerebral infarction. Undetectable mtDNA4977 may be a marker or risk factor for ischemic stroke.
Highlights
MtDNA4977 was undetected in 6.94% subjects, and these individuals had a higher prevalence of stroke than those with detectable mtDNA4977 (OR: 0.181, 95% CI 0.041–0.798, p = 0.024)
Mounting evidence suggests that mitochondria dysfunction and the accumulation of mitochondria DNA damage plays an important role in the development of atherosclerotic lesions
After adjusting for confounding factors, there was no correlation between mtDNA4977 amount and infarction risk, recurrent stroke (OR = 1.106, 95% CI = 0.952–1.285, p = 0.187), and stroke severity (OR = 0.953, 95% CI = 0.778–1.168, p = 0.645) (Table 5)
Summary
Mounting evidence suggests that mitochondria dysfunction and the accumulation of mitochondria DNA (mtDNA) damage plays an important role in the development of atherosclerotic lesions. Evidence suggests that somatic mtDNA alternations are associated with coronary artery disease (CAD) and atherosclerosis. Ballinger et al [6] showed that atherosclerotic aortas had increased numbers of mtDNA oxidative lesions compared to normal aortas. Previous studies have shown that patients with CAD have an increased abundance of mtDNA 4977 bp deletions (mtDNA4977) in the heart and in circulating leukocytes [7, 8]. A significantly higher prevalence of mtDNA4977 and higher relative amounts of the deletion were identified in CAD patients compared to healthy control subjects (26.2% versus 4.5%; p = 0.03 and 0.089 ± 0.02% versus 0.009 ± 0.009; p = 0.02) [9]. Editor: Johannes Boltze, Fraunhofer Research Institution of Marine Biotechnology, GERMANY
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
